SCYX
SCYNEXIS, Inc.
NASDAQHealthcareDrug Manufacturers - Specialty & GenericUS
Rating:C-
Company Profile
CEO
David Gonzalez Angulo
IPO Date
2014-05-02
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Exchange
NASDAQ
Country
US
SCYNEXIS, Inc.
CEO
David Gonzalez Angulo
IPO Date
2014-05-02
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Exchange
NASDAQ
Country
US
| 108,695 |
| $1.20 |
| 2 Feb 2026 | Macleod ivor | Chief Financial Officer | A-Award | Acquired | 129,833 | $0.00 |
| 2 Feb 2026 | Sukenick Scott | Chief Legal Officer | A-Award | Acquired | 129,833 | $0.00 |
| 2 Feb 2026 | Angulo Gonzalez David | director, officer: Chief Executive Officer | A-Award | Acquired | 391,333 | $0.00 |
| 21 Oct 2025 | Angulo Gonzalez David | director, officer: Chief Executive Officer | A-Award | Acquired | 32,500 | $0.76 |
| 30 Jun 2025 | Tinmouth Brian Philippe | director | A-Award | Acquired | 23,000 | $0.00 |
| 30 Jun 2025 | Tinmouth Brian Philippe | director | A-Award | Acquired | 23,000 | $0.74 |
| 30 Jun 2025 | Macdonald Guy | director | A-Award | Acquired | 23,000 | $0.00 |
| 30 Jun 2025 | Macdonald Guy | director | A-Award | Acquired | 23,000 | $0.74 |